November 6, 2023 11:31 AM EST
News Briefing

Zen­tal­is shakes up PhI­II plans in ovar­i­an can­cer; Halozyme's deal with Acu­men; Ko­r­ro's $117M pri­vate place­ment

Lei Lei Wu

News Reporter

Jaimy Lee

Deputy Editor

Zen­tal­is Phar­ma shakes up plans for Phase III in ovar­i­an can­cer: Zen­tal­is an­nounced Mon­day that it is no longer plan­ning to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times